Position in TLRY
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$170,109
New position
Shares Held
26,292
first reported quarter
Ownership
0.023%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 71%
Shared 0%
None 29%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026CAPTRUST FINANCIAL ADVISORS holds $56,556,259 across 24 Drug Manufacturers - Specialty & Generic names. TLRY ranks #17 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
216,286 | $25,567,168 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
11,253 | $6,672,803 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
37,584 | $4,951,316 | |
| 4 | HLN |
Haleon plc
|
371,702 | $3,720,737 | |
| 5 | TAK |
Takeda Pharmaceutical Co Ltd
|
158,629 | $2,937,809 | |
| 6 | VTRS |
Viatris Inc
|
199,616 | $2,696,812 | |
| 7 | SUPN |
Supernus Pharmaceuticals, Inc.
|
40,252 | $2,080,625 | |
| 8 | HROW |
Harrow, Inc.
|
56,788 | $2,002,344 |
All Filings in TLRY
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $170,109 | 26,292 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||